Xiaodan Wang , Lixia Zhuo , Wei Wu , Dongqi Cui , Huan Sun , Feidi Wang , Peiyu Luo , Yixuan Lyu , Yifang Zhai , Jiao Han , Yan Li , Xin Shen , Ying Xiao , Ruosong Ai
{"title":"前扣带皮层功能障碍是mt2缺陷小鼠焦虑样行为的基础","authors":"Xiaodan Wang , Lixia Zhuo , Wei Wu , Dongqi Cui , Huan Sun , Feidi Wang , Peiyu Luo , Yixuan Lyu , Yifang Zhai , Jiao Han , Yan Li , Xin Shen , Ying Xiao , Ruosong Ai","doi":"10.1016/j.neuropharm.2025.110652","DOIUrl":null,"url":null,"abstract":"<div><div>Anxiety disorders are prevalent mental health conditions with significant impacts on quality of life. While the melatonin type 2 receptor (MT2) has been implicated in anxiety, its specific role and neural mechanisms remain unclear. This study investigates the deficiency of MT2 induces robust anxiety-like phenotypes in mice, mediated through anterior cingulate cortex (ACC) dysfunction. Global knockout (MT2-KO) and conditional ACC-targeted deletion (MT2-cKO) models consistently demonstrated increased anxiety responses in standardized behavioral batteries, establishing ACC MT2 as a key neuromodulator in emotional regulation. Electrophysiological recordings revealed that MT2 deficiency disrupted excitatory-inhibitory (E/I) balance of ACC pyramidal neurons. Chemogenetic activation of MT2-positive neurons in the ACC restored E/I balance and ameliorated anxiety-like behaviors in chronic immobility stress (CIS) model mice. These findings establish MT2 as a pivotal regulator of ACC neurocircuitry and implicate targeted modulation of ACC MT2 signaling as a potential therapeutic strategy for anxiety disorders.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"279 ","pages":"Article 110652"},"PeriodicalIF":4.6000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anterior cingulate cortex dysfunction underlies anxiety-like behaviors in MT2-deficient mice\",\"authors\":\"Xiaodan Wang , Lixia Zhuo , Wei Wu , Dongqi Cui , Huan Sun , Feidi Wang , Peiyu Luo , Yixuan Lyu , Yifang Zhai , Jiao Han , Yan Li , Xin Shen , Ying Xiao , Ruosong Ai\",\"doi\":\"10.1016/j.neuropharm.2025.110652\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Anxiety disorders are prevalent mental health conditions with significant impacts on quality of life. While the melatonin type 2 receptor (MT2) has been implicated in anxiety, its specific role and neural mechanisms remain unclear. This study investigates the deficiency of MT2 induces robust anxiety-like phenotypes in mice, mediated through anterior cingulate cortex (ACC) dysfunction. Global knockout (MT2-KO) and conditional ACC-targeted deletion (MT2-cKO) models consistently demonstrated increased anxiety responses in standardized behavioral batteries, establishing ACC MT2 as a key neuromodulator in emotional regulation. Electrophysiological recordings revealed that MT2 deficiency disrupted excitatory-inhibitory (E/I) balance of ACC pyramidal neurons. Chemogenetic activation of MT2-positive neurons in the ACC restored E/I balance and ameliorated anxiety-like behaviors in chronic immobility stress (CIS) model mice. These findings establish MT2 as a pivotal regulator of ACC neurocircuitry and implicate targeted modulation of ACC MT2 signaling as a potential therapeutic strategy for anxiety disorders.</div></div>\",\"PeriodicalId\":19139,\"journal\":{\"name\":\"Neuropharmacology\",\"volume\":\"279 \",\"pages\":\"Article 110652\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuropharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0028390825003600\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0028390825003600","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Anterior cingulate cortex dysfunction underlies anxiety-like behaviors in MT2-deficient mice
Anxiety disorders are prevalent mental health conditions with significant impacts on quality of life. While the melatonin type 2 receptor (MT2) has been implicated in anxiety, its specific role and neural mechanisms remain unclear. This study investigates the deficiency of MT2 induces robust anxiety-like phenotypes in mice, mediated through anterior cingulate cortex (ACC) dysfunction. Global knockout (MT2-KO) and conditional ACC-targeted deletion (MT2-cKO) models consistently demonstrated increased anxiety responses in standardized behavioral batteries, establishing ACC MT2 as a key neuromodulator in emotional regulation. Electrophysiological recordings revealed that MT2 deficiency disrupted excitatory-inhibitory (E/I) balance of ACC pyramidal neurons. Chemogenetic activation of MT2-positive neurons in the ACC restored E/I balance and ameliorated anxiety-like behaviors in chronic immobility stress (CIS) model mice. These findings establish MT2 as a pivotal regulator of ACC neurocircuitry and implicate targeted modulation of ACC MT2 signaling as a potential therapeutic strategy for anxiety disorders.
期刊介绍:
Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).